Human African trypanosomiasis (HAT, sleeping sickness) is one of the WHO's 21 neglected tropical diseases (NTDs) and threatens an estimated 70 million people in Africa. Each year, approximately 1.5 billion people need treatment for NTDs, which account for 120,000 deaths and 14.1 million disability-adjusted life years. The WHO Global Plan 2021–2030 aims for 90% elimination of NTDs in people in need of intervention by 2030. So far, 57 countries have eliminated at least one NTD, and in 2023 867 million people were treated. Kenya has achieved the elimination of HAT as a public health problem through enhanced surveillance in 12 health facilities in six endemic districts, equipped with diagnostic tools and trained personnel. The country also monitors tsetse flies and animal trypanosomiasis with the support of KENTTEC. After WHO validation, post-validation surveillance continues to detect possible recurrence, with available drugs from Bayer AG and Sanofi. These activities confirm the elimination of HAT in Kenya as a significant milestone in the fight against NTDs.